Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy

Hepatology Research

Volumn 45, Issue 9, 2015, Pages 949-959

  Terashima, Takeshi ^a   Yamashita, Tatsuya ^a   Iida, Noriho ^a   Yamashita, Taro ^a   Nakagawa, Hidetoshi ^a   Arai, Kuniaki ^a   Kitamura, Kazuya ^a   Kagaya, Takashi ^a   Sakai, Yoshio ^a   Mizukoshi, Eishiro ^a   Honda, Masao ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hepatic arterial infusion chemotherapy; Hepatocellular carcinoma; Neutrophil lymphocyte ratio; Predictive factor; Prognostic factor

Indexed keywords

ALPHA FETOPROTEIN; ALPHA2B INTERFERON; C REACTIVE PROTEIN; CISPLATIN; DECARBOXYPROTHROMBIN; FLUOROURACIL; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON ALPHA2B; PLATELET DERIVED GROWTH FACTOR BB; SORAFENIB;

ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVOR; CHILD PUGH SCORE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR GROWTH; TUMOR INVASION;

EID: 84941022115     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12436     Document Type: Article

References (29)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Lee JM, Yoon JH, Kim KW. Diagnosis of hepatocellular carcinoma: newer radiological tools. Semin Oncol 2012; 39: 399-409.
3. Takizawa D, Kakizaki S, Sohara N etal. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig Dis Sci 2007; 52: 3290-3295.
4. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
5. Kaneko S, Furuse J, Kudo M etal. Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcioma 2010 update. Hepatol Res 2012; 42: 523-542.
6. Terashima T, Yamashita T, Arai K etal. Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib. Hepatol Research 2014; 44: 1179-1185.
7. Song DS, Song MJ, Bae SH etal. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol 2014; [Epub ahead of print]. doi: 10.1007/s00535-014-0978-3.
8. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444.
9. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
10. Chen L, Zhang Q, Chang W, Du Y, Zhang H, Gao G. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer 2012; 48: 1977-1987.
11. Templeton AJ, McNamara MG, Seruga B etal. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; [Epub ahead of print]. doi: 10.1093/jnci/dju124.
12. Bertuzzo VR, Cescon M, Ravaioli M etal. Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers. Tlansplantation. 2011; 91: 1279-1285.
13. Chen TM, Lin CC, Huang PT, Wen CF. Neutrophil-to-lymphocyte ration associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol 2012; 27: 553-561.
14. McNally ME, Martinez A, Khabiri H etal. Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. Ann Surg Oncol 2013; 20: 923-928.
15. Motomura T, Shirabe K, Mano Y etal. neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol 2013; 58: 58-64.
16. Pinato DJ, Sharma R. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma. Transl Res 2012; 160: 146-152.
17. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
18. Yamashita T, Arai K, Sunagozaka H etal. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 2011; 81: 281-290.
19. Arihara F, Mizukoshi E, Kitahara M etal. Increase of CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother 2013; 62: 1421-1430.
20. Eisenhauer EA, Therasse P, Bogaerts J etal. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
21. Pinato DJ, Stebbing J, Ishizuka M etal. A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol 2012; 57: 1013-1020.
22. Hsu CY, Lee YH, Hsia CY etal. Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer System. Hepatology 2013; 57: 112-119.
23. Morimoto M, Numata K, Moriya S etal. Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment. Anticancer Res 2012; 32: 619-623.
24. Lee MH, Kim SU, Kim do Y etal. Early on-treatment predictions of clinical outcome using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2012; 27: 313-322.
25. Oxnard GR, Morris MJ, Hodi FS etal. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst 2012; 104: 1534-1541.
26. Wada Y, Yoshida K, Tsutani Y etal. Neutrophil elastase induces cell proliferation and migration by the release of TGF-alpha, PDGF and VEGF in esophageal cell lines. Oncol Rep 2007; 17: 161-167.
27. Miyahara K, Nouso K, Morimoto Y etal. Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma. Br J Cancer 2013; 109: 2072-2078.
28. Lau CK, Yang ZF, Ho DW etal. An Akt/Hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clin Cancer Res 2009; 15: 3462-3471.
29. Inaba Y, Kanai F, Aramaki T etal. A randomized phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolization. Eur J Cancer 2013; 49: 2832-2840.